ArticleCase reports in dermatology
Advanced Combination Therapy with Tofacitinib and Biologic Agents for Psoriasis and Psoriatic Arthritis: A Case Series.
Article in Case reports in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The treatment of psoriatic disease is frequently complex, and many patients do not respond to the available therapies. While novel therapies like biologics and Janus kinase (JAK) inhibitors have been utilized individually to treat psoriatic disease, limited data are available regarding the effect and potential side effects of combining these agents in treatment. Case Presentations: We present a case series of 6 patients with psoriasis and psoriatic arthritis or inflammatory bowel disease treated with tofacitinib and a biologic (5 treated with IL-23 inhibitors and 1 with an IL-17 inhibitor). All patients had tried multiple treatments prior to initiating combination therapy with tofacitinib and a biologic. Out of the 6 patients, 2 remained on combination therapy, while 4 discontinued either one or both drugs due to lack of response or intolerance. We observed a varying effectiveness of the combination therapy, with an overall positive effect on psoriasis and psoriatic arthritis but no effect on inflammatory bowel disease. No major treatment-emergent adverse events occurred during the combination therapy period. Conclusion: This case series adds to the sparse data on combining biologics and JAK inhibitors for the treatment of psoriatic disease. Advanced combination therapy with a JAK inhibitor and a targeted biologic agent may represent a relevant treatment option in selected cases of treatment-refractory psoriatic disease. However, larger studies are needed to establish the safety and efficacy of this combination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.